Introduction {#Sec1}
============

The study of embryonic stem (ES) cells will continue to yield important discoveries in the areas of cell differentiation and growth, tissue engineering, and regenerative medicine. The ES cells are derived from the inner cell mass of blastocyst embryos, have unlimited proliferation, and are the precursor to the three embryonic germ layers \[[@CR1], [@CR2]\]. To efficiently study ES cells and successfully expand their potential clinical applications, a rapid, reliable, and simple technique is needed to deliver genes to stem cells. Typically, gene delivery techniques have been divided into two categories: *viral* and *non-viral* gene delivery. Viral delivery uses the backbone of a viral genome, such as retrovirus, lentivirus, adenovirus, and adeno-associated virus (AAV), with insertion of the gene(s) of interest to be expressed in the stem cell. The more commonly used non-viral plasmid delivery systems include liposome, electroporation, and nucleofection-based, though newer techniques such as ultrasound \[[@CR3], [@CR4]\], microinjection \[[@CR5]\], nuclear transfer \[[@CR6], [@CR7]\], and molecular-vibration-mediated delivery \[[@CR8]\] have also been examined, among other techniques.

The advantages of using non-viral delivery compared to viral vector delivery include decreased immunogenicity and less insertional mutagenesis. However, the disadvantages of non-viral delivery may include decreased transfection efficiency and a shorter period of transgene expression which may limit long-term studies. For example, the transfection efficiency and viability of hES cells following electroporation has been shown to vary depending on the specific voltage and capacity settings \[[@CR9], [@CR10]\]. Cell survival rates following electroporation are typically low at 24 to 48 h and often not recorded, though range from \>60% at 1 to 2 h \[[@CR9]\], 73% at 2 to 3 h \[[@CR11]\], to a median rate of 19% at 48 h \[[@CR12]\].

In addition, the efficiency of gene transfer with cationic liposomes varies significantly based on the commercial preparation \[[@CR13]\]. Liposome preparations may have different aliphatic chain lengths and structural compositions, as well as various associated anions. Nucleofection, a liposomal-based electroporation system that can be adapted with appropriate buffers for different cell lines, has demonstrated a significantly higher level of transfection efficiency, with results of 32% to 66% of viable H9.2 cells at 24 h \[[@CR11]\] and 20% to 22% of viable H1 cells at 72 h \[[@CR14]\]. The survival rate following nucleofection has been demonstrated at 74% with a control transfection at 48 h and 50% with transfection of GFP at 48 h \[[@CR15]\]. Lastly, despite the disadvantages associated with the use of viral vectors for gene transfer, the lentiviral systems have reliably demonstrated efficient transduction into hES cells. Lentiviral transduction has demonstrated efficiencies of 20% at low viral titers to \>80% at high viral titer \[[@CR16], [@CR17]\].

Although various studies have examined the gene-transfer efficiency to hES cells *in vitro* as highlighted above, few have focused on a direct comparison of these techniques. In this study, we examine lipofection, electroporation, nucleofection, and lentiviral transduction of H1 and H9 hES cell lines to identify the most efficient, reliable, and simple gene-transfer system for *in vitro* and *in vivo* applications. Using a double-fusion plasmid construct expressing eGFP and Fluc, the transfection efficiency was carefully demonstrated for each protocol. Stable cell lines expressing the bi-fusion construct were generated by lentiviral transduction and nucleofection. Various well-characterized stem cell markers, including SSEA-4 and Oct4, were assayed to ensure that the hES cells continued to express the appropriate markers following treatment. Finally, bioluminescence imaging was used to facilitate non-invasive monitoring of transplanted hES cells *in vivo*.

Materials and Methods {#Sec2}
=====================

**Culture of Undifferentiated hES Cells** H1 and H9 hES cells were obtained from Wicell (Madison, WI). hES cells were maintained on irradiated mouse embryonic fibroblasts (MEFs) at 5% CO~2~ in medium containing Knockout-Dulbecco's modified Eagle medium (KO-DMEM), 20% serum replacement, 1% nonessential amino acids, 1 mM [l]{.smallcaps}-glutamine, 0.1 mM β-mercaptoethanol, and 4 ng/ml fibroblast growth factor-2 (FGF-2; GIBCO BRL). The cells were passaged in a 4-day cycle by incubating with 1 mg/ml collagenase IV at 37***°***C for 45 min, maintaining the cells in small clumps. To avoid contamination by MEFs in the transfection (liposome, electroporation, nucleofection) analysis, the hES cells were cultured on Matrigel in MEF-conditioned medium for one passage prior to transfection. Approximately, 2 × 10^4^/cm^2^ cells were plated uniformly in six-well plates prior to transfection. Samples of the cells were immunostained with anti-SSEA-4 (Chemicon, Temecula, CA) and anti-Oct-4 (Santa Cruz Biotechnology, Santa Cruz, CA) antibodies. Immunofluorescent labeling was analyzed using a Zeiss LSM 510 Confocal Laser Scanning Microscope equipped with a Coherent Mira 900 tunable Ti:sapphire laser for two-photon excitation (Zeiss, Minneapolis, MN).

**Construction of pUb-eGFP-Fluc and pUb-eGFP-Fluc-SV40-neomycin** The pUb-eGFP-Fluc construct used for lentiviral transduction has been described previously \[[@CR18]\]. The pUb-eGFP-Fluc-SV40-neomycin was generated by cleaving pUb-GFP-Fluc at the *Bam*H1 restriction enzymes and blunt-end ligating the SV40-neomycin construct. This plasmid was used for stable transfection of hES cells using neomycin as a selection marker.

**Plasmid Transfection Methods** (a) Lipofection: lipofection was performed 1 day after plating H1 and H9 hES cells (4--5 × 10^5^/well) onto Matrigel at a confluency of 60--70%. Qiagen lipofection 2000 was used according to the manufacturer's protocol. Briefly, 5 μg of plasmid DNA (pUb-eGFP-Fluc) was diluted in 250 μl of KO-DMEM followed by addition of 10 μl of liposomal reagent. The mixture was incubated for 15--20 min at room temperature. The mixture was then added to 1,000 μl of pre-warmed conditioned medium and transferred to one well of a six-well plates. (b) Electroporation: 5 μg of plasmid DNA (pUb-eGFP-Fluc) was diluted in 500 μl of phosphate-buffered saline (PBS) and added to 4--5 × 10^5^ hES H1 and H9 cells suspended in 500 μl of hES culture medium. Electroporation was performed in a 4-mm gap cuvette using a Gene Pulser (BioRad, München, Germany) with the electric parameters set at 300 V and 220 μF. After pulsing, the cells were incubated in the cuvette at room temperature for 10 min. The cells were transferred to new medium and plated onto Matrigel-coated six-well plates at a density of 2 × 10^5^ cells/cm^2^. Each plate was analyzed for eGFP expression under a fluorescence microscope at 24, 48, and 72 h post-electroporation. (c) Nucleofection: 4-5 × 10^5^ hES H1 and H9 cells were centrifuged for 5 min at 800 rpm and 4°C. The culture medium was removed and cells were resuspended in 100 μl of the nucleofector solution (Amaxa Biosystems, Cologne, Germany). DNA (5 μg) was added, cells and DNA were gently mixed, and cells were electroporated using the Nucleofector™ device (Amaxa Biosystems). Transfections were performed with a program (A23) that was selected in a series of pilot transfection experiments with the eGFP reporter gene and proven to result in the highest transfection efficiency. Directly after transfection, hES cells were placed into the culture medium.

**Lentiviral Vector Preparation and Transduction** A self-inactivating lentivirus was prepared by transient transfection of 293 T cells as described previously \[[@CR16], [@CR19]\]. Briefly, 12 µg of the HIV-1 packaging plasmid (peGFP-Fluc/pRRE; delta-8.9) containing the eGFP-Fluc reporter gene were cotransfected into 293 T cells with 9 µg of vesicular stomatitis virus G glycoprotein-pseudotyped envelope vector (pVSV-G), and 6.25 µg of REV plasmid (pRSV-REV). Lentivirus supernatant was collected after 72 h and concentrated by sediment centrifugation with SW29 rotor at 50,000×*g* for 2 hours. Concentrated virus was titrated on 293 T cells. hES H1 and H9 cells (4--5 × 10^5^) were incubated with virus particles at MOI of 10 and 8 µg/ml polybrene (Sigma). The media was changed after 12 h by fresh medium.

**Generation of Stable Cell Line** Stable hES cell lines were generated by fluorescence-activated cell sorting (FACS) in the lentiviral transduction group and by G418 selection (50--100 µg/ml) over 2 weeks in the nucleofection group. Colonies were isolated, propagated, and analyzed for eGFP expression and Fluc activity.

**Cell Viability Analysis** Cell viability was determined using dissociated cells prior to plating, as well as at 24 and 48 h after transfection. Viability was measured using trypan blue exclusion and expressed as a percentage of the initial number of cells used for each transfection.

**Immunohistochemistry** The H1 and H9 hES cells treated with the various transfection protocols were plated onto cover slips within six-well plates, fixed in 5% paraformaldehyde for 1 min, and blocked with 1% bovine serum albumin in PBS. They were incubated with the primary antibody in PBS at 37°C for 1 h, followed by several PBS washes, and incubation with a secondary antibody at 37°C for 1 h, with final PBS washes. Slides were mounted with Vectorshield (Vector Laboratories, Inc., Burlingame, CA, USA).

**Fluorescence-activated Cell Sorter Analysis** Twenty-four hours after transfection, the cells were washed twice with KO-DMEM and dissociated with Accutase II. After centrifugation, the cells were resuspended at 1 × 10^6^ cells/ml in PBS and stored on ice for a maximum of 1 h before analysis. Acquisition was performed on a FACS Calibur system (BD Biosciences, Heidelberg, Germany) and samples were analyzed using FlowJo software (Tree Star Inc., Ashland, OR). Analysis-gating criteria for eGFP-expressing cells were set according to the level of auto-fluorescence of a non-transfected control.

**Transplantation of hES Cells into Nude Mice** Harvested control hES and stable hES-DF cells (transduced with lentivirus) were kept on ice for \<30 min for optimal viability. Adult immunodeficient nu/nu mice (*n* = 5) were injected subcutaneously with 1 × 10^6^ hES-DF cells in 50 µL of PBS. Control animals (*n* = 3) received 1 × 10^6^ non-transduced hES cells. All animals had an uneventful recovery and underwent bioluminescence imaging at various time points. Study protocols were approved by the Stanford Animal Research Committee.

**Optical Bioluminescence Imaging of hES Cell Transplantation** Bioluminescence imaging was performed with the Xenogen In Vivo Imaging System (IVIS, Alameda, CA). Following intraperitoneal injection of the reporter probe [d]{.smallcaps}-luciferin (375 mg/kg body weight), animals were imaged for 30 min with 1-min acquisition intervals. The same mice were scanned at various time points for a 6-week period according to the specific study design. Bioluminescence was quantified in units of maximum photons per second per centimeter squared per steradian (P s^−1^ cm^−2^ sr^−1^), as described previously \[[@CR18]\].

**Statistical Analysis** Quantitative data were expressed as mean ± SD. Means were compared using one-way ANOVA and the Student *t* test. *P* values of less than 0.05 were considered statistically significant.

Results {#Sec3}
=======

**hES Cells Maintained on a Feeder-free Culture System Express Stem Cell Markers** Previous studies have detailed the need to separate hES cells from contaminant feeder layer cells prior to the initiation of studies \[[@CR20]\]. For our studies, the H9 and H1 cells were reseeded onto Matrigel-coated plates to eliminate any possible contaminating effects of the MEF feeder layer. Additional studies were performed on these hES cells to confirm that separation from the feeder layer had not changed the basic characteristics of the cells. The cell doubling time was tested by cell counting, which revealed similar results between the hES cells on feeder layer and feeder-free plates (37 ± 3.4 h vs. 36 ± 2.1 h; *P* = NS). The two cell lines showed the same morphology under brightfield microscopy (Fig. [1](#Fig1){ref-type="fig"}). Immunohistochemistry staining also showed similar expression pattern of Oct-4 and SSEA-4 under fluorescence microscopy for H9 and H1 hES cells. These results confirm that H9 and H1 hES cells grown in a feeder-free cell culture system maintained similar growth and surface marker expression characteristics compared to hES cells grown on conventional feeder layers. Fig. 1.Immunohistochemistry of stem cell markers on undifferentiated H9 and H1 cell lines grown in feeder-cell free cultures *in vitro*. H9 and H1 cells were reseeded onto Matrigel-coated plates. Brightfield and immunohistochemistry staining with fluorescence microscopy for Oct-4 and SSEA-4 stem cell markers was performed. DAPI staining is used as a nuclear marker (*scale bar* = 50 µm in *mid-* and *right* fluorescence staining; 200 µm in *left* brightfield).

**Lentivirus transduction and Plasmid Nucleofection Demonstrate Higher Efficiencies *in vitro*** Following a review of the literature (previously detailed) \[[@CR11], [@CR21]--[@CR23]\], transfection conditions yielding the highest efficiencies for hES cells were utilized for each transfection protocol. Within 24 h, there was a significant difference in gene-transfer efficiencies in H9 and H1 cells. In particular, lentiviral transduction demonstrated the highest level of Fluc gene expression, with bioluminescence measurements of 0.95 ± 0.13 × 10^6^ photons/s for H9 and 1.37 ± 0.16 × 10^6^ for H1. Nucleofection demonstrated lower transfection efficiency compared to lentiviral transduction (3.2 ± 3.9 × 10^5^ photons/s for H9 and 5.6 ± 0.12 × 10^5^ for H1; *P* \< 0.05 for both). Importantly, both electroporation and lipofection had very low transfection efficiencies compared to lentiviral transduction and nucleofection (Fig. [2](#Fig2){ref-type="fig"}). In our studies, the H1 cell line had higher transfection efficiency than the H9 hES cell line for all protocols tested, suggesting varying susceptibility to gene transfer in different hES lines. Fig. 2.Transfection and transduction of H9 and H1 hES cells *in vitro* with each of the transfection protocols. (**a**) H9 and H1 cells were seeded onto feeder-cell free Matrigel-coated six-well plates after transfection with plasmid alone (*Plasmid*), lipofection (*Lipo+P*), electroporation (*Electro+P*), nucleofection (*Nucleo+P*), and transduction with lentivirus (*LentiV*). (**b**) The cells were examined using bioluminescence imaging of Fluc activities after transfection. The quantitative measurements are shown 24 h after gene delivery.

**FACS Analysis of eGFP Expression in H1 and H9 hES Cell Lines** The double-fusion construct allows us to simultaneously analyze eGFP by FACS and Fluc by bioluminescence imaging. Consistent with the Fluc bioluminescence activity shown above, the eGFP expression was highest in lentiviral-transduced cells followed by nucleofection-transfected cells (Fig. [3](#Fig3){ref-type="fig"}). Lentiviral transduction demonstrated the highest transduction efficiency, with 25.3 ± 4.8% and 22.4 ± 6.5% positive eGFP cells for H1 and H9, respectively. Nucleofection demonstrated transfection efficiency of 16.1 ± 3.6% (H1) and 5.8 ± 3.2% (H9). Low eGFP expression was again seen in electroporation (2.1 ± 0.4% (H1) and 1.9 ± 0.3% (H9)) and lipofection (1.5 ± 0.5% (H1) and 1.3 ± 0.2% (H9)). Fig. 3.Measurement of eGFP expression using flow cytometry analysis of H1 and H9 hES cell lines transfected with each protocol. The bi-fusion pUb-eGFP-Fluc construct was transfected into H9 and H1 hES cells using lipofection (*Lipo+P*), electroporation (*Electro+P*), nucleofection (*Nucleo+P*), and transduction with lentivirus (*LentiV*). eGFP expression was measured using FACS analysis.

**Higher Cell Viability Demonstrated in lentiviral-transduced Cells** The protocols and expertise to isolate and grow sufficient quantities of hES cells are complex and technically challenging. Due to this laborious process, a high hES cell viability following gene transfer is essential. It is commonly known that electroporation of hES cells results in significant cell death, despite efforts to optimize and minimize the energy delivered \[[@CR9]\]. The use of lentivirus, on the other hand, has previously demonstrated high levels of cell viability following transduction \[[@CR16], [@CR17]\]. To address this issue, we examined the cell morphology and assessed the cell viability using trypan blue exclusion at 24 h following gene transfer with the various protocols. The H1 and H9 cells were examined by overlaying brightfield microscopy with eGFP fluorescence. H9 cells clearly demonstrate significantly lower viability in electroporation treated cells (Fig. [4](#Fig4){ref-type="fig"}), followed by nucleofection-treated cells. Similar results were obtained for H1 cells (data not shown). The trypan blue assay details the cell viability following electroporation at 62 ± 11% (H1) and 42 ± 10% (H9)) followed by nucleofection at 25 ± 9% (H1) and 30 ± 15% (H9) at 24 h. By contrast, the other four groups all showed greater than 95% viability. Fig. 4.Viability of H9 and H1 hES cells *in vitro* following transfection with the various gene-transfer protocols. H9 and H1 hES cells were examined at 24 h following transfection with lipofection (*Lipo+P*), electroporation (*Electro+P*), nucleofection (*Nucleo+P*) and transduction with lentivirus (*LentiV*). Cell morphology and trypan blue exclusion assay was performed to measure cell viability. (**a**) Fluorescence microscopy of representative H1 cells. *Scale bar* = 100 µm. (**b**) Viability of each transfected cell lines at 24 h as measured using the trypan blue assay.

***In vivo* Imaging to Monitor hES Cell Survival, Proliferation, and Teratoma Formation** The ability to monitor transplanted hES cells *in vivo* without sacrificing the animals has been made possible by incorporating newer imaging technologies such as optical bioluminescence or positron-emission tomography \[[@CR24]\]. Following subcutaneous transplantation, bioluminescence imaging was performed on days 2, 7, 14, 35, 42, and 56 (Fig. [5a](#Fig5){ref-type="fig"}). H9-DF cells (via stable lentiviral transduction) showed persistent engraftment and survival as measured by bioluminescence activities: day 2 (55.2 ± 14.3 × 10^6^), day 7 (21.2 ± 6.1 × 10^6^), day 14 (17.2 ± 5.0 × 10^6^), day 35 (19.5 ± 3.2 × 10^6^), day 42 (28.1 ± 7.2 × 10^6^), and day 56 (65.3 ± 14.1 × 10^6^ p/s/cm^2^/sr). Control H9 cells (not expressing the GFP-Fluc) cannot be detected as expected. Following imaging at day 56, animals were sacrificed and the teratoma explanted. Histologic analysis of control hES and hES-DF teratomas shows mixed regions of endodermal, mesodermal, and ectodermal differentiation (Fig. [5b](#Fig5){ref-type="fig"}). Thus, the histological data suggest that lentiviral transduction did not significantly affect the differentiation of hES cells into the three germ layer cell types *in vivo*. Fig. 5.Optical bioluminescence imaging of stably expressed hES cells *in vivo* over time, with demonstration of proliferation and teratoma formation. The pUb-eGFP-Fluc-SV40-Puro construct was stably expressed in H9 cells by transduction with replication-incompetent lentivirus. Stable colonies (*hES-DF*) were selected by drug selection over 2 weeks and then injected subcutaneously into right shoulder of nude mice. Control untransduced H9 hES cells were injected into left shoulder. (**a**) *In vivo* bioluminescence imaging of the hES-DF cells on days 2, 7, 14, 35, 42, and 56. (**b**) Histology of the H9 hES cells stably expressing eGFP-Fluc in nude mice were examined through 56 days. Teratoma formation was demonstrated by histology at week 8 weeks after subcutaneous injection: (*A*) rosette consistent with neuroectodermal differentiation (ectoderm), (*B*) cartilage formation (mesoderm), (*C*) respiratory epithelium with ciliated columnar, and (*D*) mucin-producing goblet cells (endoderm) surrounded with mesenchymal cells (mesoderm). *Scale bar* = 50 µm.

Discussion {#Sec4}
==========

To date, the ability to manipulate stem cells for clinical applications has been limited by techniques in basic molecular and cellular biology, as well as our understanding of ES cell biology. Protocols for gene transfer that had demonstrated significant promise in mouse embryonic stem (mES) cells, such as electroporation and lipofection, are less efficient in hES cells \[[@CR12]\]. In general, mES cells have demonstrated higher levels of transfection efficiency, whereas hES cells are notoriously difficult to transfect. This has led to optimizing existing protocols, as well as the discovery of novel and cutting-edge techniques that have increased transfection efficiency into hES cells. It is important that if these protocols are to be used routinely as an efficient, simple, and reproducible method of gene transfer, the effect on hES cell growth and differentiation should not be affected, and transgene expression should remain intact over prolonged periods of time. Using a double-fusion reporter gene that allows for non-invasive "real-time" imaging, we have examined the transfection and transduction efficiency of various protocols on the H1 and H9 hES cell lines *in vitro* and *in vivo*.

Few studies have performed side-by-side comparison of the efficiency of the various transfection and transduction methods available for gene transfer to hES cells. Nucleofection of hES cells has shown superior transfection efficiency compared to lipofection and electroporation for H9.2 cells \[[@CR11]\], and in adipose-tissue-derived stem cells \[[@CR21]\]. We have examined the protocols from these studies, as well as numerous other studies to identify the optimal experimental conditions for electroporation, lipofection, nucleofection, and lentiviral transduction using male H1 and female H9 cells, and have compared their transfection or transduction efficiency *in vitro*. The double-fusion construct (expressing eGFP and the Fluc) allowed for rapid, reproducible, and real-time monitoring of cells over an extended period of time. Lentiviral transduction demonstrated the highest level of gene transfer (22--25%) with the best viability following treatment (\>95%). The highest efficiency using a non-viral protocol was demonstrated by nucleofection, though with a mildly decreased level of viability (70--75%). Electroporation and lipofection demonstrated very low levels of transfection efficiency, which is consistent with previous studies reported \[[@CR23]\]. Viability following treatment with electroporation was poor (20--25%) despite attempts to optimize the specific voltage and capacity settings. For each modality, expression of the eGFP-Fluc double-fusion reporter gene did not appear to affect cell growth and viability.

Previous studies have examined transient transfection of various hES cell lines *in vitro*, and production of stable human ES cell lines \[[@CR16], [@CR23], [@CR25]\]. However, few studies have generated stable hES cell lines and monitored their growth *in vivo* using noninvasive bioluminescence imaging. In this study, we have also generated stable cell lines with lentiviral transduction and plasmid nucleofection protocols using the double-fusion (DF) reporter gene construct and monitored their growth and differentiation *in vivo* over several months. Immunofluorescence and histological analysis demonstrates that the stable hES cell lines consist of undifferentiated cells that express numerous stem cell markers, including SSEA4 and Oct4. After several weeks, these undifferentiated cells develop into subcutaneous teratomas. In addition, the DF reporter gene did not affect hES cell viability, growth, and differentiation, similar to previous report on mES cells \[[@CR24]\]. Of note, the higher number of stable cell lines (\~twofold higher) generated by lentiviral transduction compared to nucleofection is likely secondary to a higher gene-transfer rate, in combination with a higher rate of viability.

Transfection and transduction protocols that can successfully transfer genes to the nucleus in a cell-cycle-independent manner will be most effective in hES cells. Lipofection (including Fugene and Exgen 500), transduction with many pseudotyped retroviral constructs (e.g., murine leukemia virus), and polymer- or polycation-based protocols require cell proliferation (mitosis) and breakdown of the nuclear envelope, or nuclear localization signal (NLS) directing transport from the cytoplasm to the nucleus. The trafficking of gene products to the nucleus has been challenging, with mixed success using well-characterized NLS signals, such as the SV40 NLS for example \[[@CR26]--[@CR28]\]. By contrast, lentivirus, adenovirus, and AAV can infect both dividing and non-dividing cells, have low cytogenicity, and can integrate their genome into the host chromosome. The use of vectors derived from retroviruses as gene-transfer vehicles in this setting has had limited success because of silencing of transgene expression. Two major mechanisms have been identified for retrovirus silencing: trans-acting factors that bind to the viral promoters in the long terminal repeats (LTRs) and methylation of the integrated retroviral genome and flanking host DNA sequences \[[@CR29]\]. Similar to the lentiviral system, electroporation is independent of cell cycle and can directly transport DNA to the nucleus. Despite efforts to optimize the specific voltage and capacity settings, survival rates and levels of transfection efficiency in hES cells have been poor. Nucleofection, on the other hand, has demonstrated higher levels of transfection efficiency with significantly improved levels of cell viability over electroporation. This technique has demonstrated the ability to ubiquitously transfect various cell lines \[[@CR30], [@CR31]\], including CD34^+^ cells and H1 cells \[[@CR14]\]. In this study, the nucleofector settings and buffer were selected based on previous studies in our lab, as well as other published reports \[[@CR27], [@CR28]\]. The ability to adapt the nucleofection parameters and buffers to various primary cell lines may further improve transfection efficiency. In addition, other studies using nucleofection have demonstrated efficient expression of siRNA \[[@CR32]\], mRNA \[[@CR22], [@CR33]\], and various small and macromolecules \[[@CR9]\].

In this study, both lentiviral transduction and plasmid nucleofection protocols successfully generated stable hES clones that stably expressed the DF reporter gene. Although lentivirus generated higher numbers of stable clones, nucleofection is a simple, reproducible, and efficient technique for transient as well as stable transfection. The double-fusion construct allowed for effective, non-invasive tracking of proliferating hES cells in nude mice, with no noticeable disruption of cell differentiation during prolonged gene expression. The lack of significant transgene silencing following *in vivo* transplantation has been previously reported \[[@CR24]\].

In summary, the ability to study the biology of hES cells requires genetic manipulation to express various transgenes. Nucleofection is an attractive transfection protocol with minimal safety concerns. It is a simple and efficient system and can be used to generate hES cell lines stably expressing reporter genes. Although this protocol can generate stable hES cell lines, the lentiviral system is more efficient and could still play a role in various applications.
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